Back to News
Market Impact: 0.15
Teva CEO on Shares Trading Directly on the NYSE
Source: Bloomberg
Healthcare & BiotechCompany Fundamentals
Teva Pharmaceuticals CEO Richard Francis discussed the company’s decision to shift its NYSE-listed shares from ADRs to direct trading and what the change means for investors. The article provides no financial targets, operating updates, or quantified impact, indicating the move is primarily a listing-structure change rather than a fundamental business development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
TEVA0.10
More News
- US estrogen supply crunch widens as women seek alternatives to scarce patches
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns